Stocksigma LogoStocksigma Logo

Tatva Chintan Pharma Chem Reports Strong Q2FY27 Results

Tatva Chintan Pharma Chem reported a 76% YoY surge in Q2FY27 revenue from operations to ₹2,173 Mn, while EBITDA (excluding other income) rose 83% YoY to

Tatva Chintan Pharma Chem Reports Strong Q2FY27 Results

Tatva Chintan Pharma Chem Ltd · Investor Presentation · 19 Oct 2026, 11:37 pm

Tatva Chintan Pharma Chem Reports Strong Q2FY27 Results Tatva Chintan Pharma Chem reported a 76% YoY surge in Q2FY27 revenue from operations to ₹2,173 Mn, while EBITDA (excluding other income) rose 83% YoY to ₹407 Mn with a 19% margin. Q2FY27 PAT surged 116% YoY to ₹215 Mn (EPS of ₹9.17). For H1FY27, revenue reached ₹3,844 Mn (up 60% YoY) and PAT expanded 126% YoY to ₹374 Mn. In Q2FY27, SDA contributed 45% of revenue, driven by EURO 7 emission standard adoption, followed by PASC at 30% and PTC at 21%.

Original exchange filing (PDF)

More announcements from Tatva Chintan Pharma Chem Ltd

All Tatva Chintan Pharma Chem Ltd announcements